Alex Zisson Managing Director

Alex focuses on investments in the biopharmaceuticals industry, specifically in pharmaceuticals, generics, drug delivery and specialty pharma, and biotechnology.

Alex is a Managing Director with H.I.G. HealthBridge Partners. He currently serves on the board of directors for Leiters Health, BioVectra, Orbus Therapeutics, Rising Pharmaceuticals, Navitas, Celerion, Click Therapeutics, and Nevakar. Previous board seats included Arvelle Therapeutics and Taconic Biosciences. Before joining H.I.G., Alex spent 13 years making similar investments at Thomas, McNerney & Partners.

Prior to Thomas, McNerney, Alex spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan). During his tenure at H&Q, Alex led research teams covering the biotechnology, specialty pharmaceuticals, large-cap pharmaceuticals, drug delivery, and diagnostics industries. After the merger of Chase H&Q and JPMorgan, Alex became the firm’s healthcare strategist. He was named twice in The Wall Street Journal All-Star Analysts Survey, including his last year at JPMorgan in which he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and ‘home run’ hitting (#8 across all industries).

Alex is the co-chair of the Business Advisory Council of the Children’s Tumor Foundation, on the advisory board for Brown University’s medical school, on the Life Sciences Council for Springboard Enterprises, a group that assists women in entrepreneurial roles, and on the Board of Advisors for Life Science Cares New York, which connects the life sciences industry with nonprofits addressing critical needs in education, health, and economic mobility. He is also a board member for the Greenwich Council of the Boy Scouts of America.

He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.